These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Use and outcomes associated with long-acting bronchodilators among patients hospitalized for chronic obstructive pulmonary disease. Lindenauer PK; Shieh MS; Pekow PS; Stefan MS Ann Am Thorac Soc; 2014 Oct; 11(8):1186-94. PubMed ID: 25167078 [TBL] [Abstract][Full Text] [Related]
33. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD. Calverley PM; Anzueto AR; Dusser D; Mueller A; Metzdorf N; Wise RA Int J Chron Obstruct Pulmon Dis; 2018; 13():1297-1308. PubMed ID: 29719385 [TBL] [Abstract][Full Text] [Related]
34. Pharmacologic Management of COPD Exacerbations: A Clinical Practice Guideline from the AAFP. Stevermer JJ; Fisher L; Lin KW; Liu R; Goodenberger D; Schellhase K; Vaughan B; Bird MD Am Fam Physician; 2021 Jul; 104(1):Online. PubMed ID: 34264593 [No Abstract] [Full Text] [Related]
35. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Hurst JR; Han MK; Singh B; Sharma S; Kaur G; de Nigris E; Holmgren U; Siddiqui MK Respir Res; 2022 Aug; 23(1):213. PubMed ID: 35999538 [TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. Kobayashi S; Hanagama M; Ishida M; Sato H; Ono M; Yamanda S; Yamada M; Aizawa H; Yanai M Int J Chron Obstruct Pulmon Dis; 2018; 13():3947-3955. PubMed ID: 30584294 [TBL] [Abstract][Full Text] [Related]
37. Relationship Between the GesEPOC 2021 Classification of Risk Levels and Phenotypes and the Incidence of Adverse Events. Golpe R; Figueira-Gonçalves JM; Esteban C; Amado-Diago CA; Aramburu A; García-Talavera I; Veiga I Arch Bronconeumol; 2022 May; 58(5):451-453. PubMed ID: 35312502 [No Abstract] [Full Text] [Related]
38. Mechanisms of Chronic Obstructive Pulmonary Disease Exacerbations. Wedzicha JA Ann Am Thorac Soc; 2015 Nov; 12 Suppl 2():S157-9. PubMed ID: 26595732 [TBL] [Abstract][Full Text] [Related]
39. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Blais L; Forget A; Ramachandran S Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680 [TBL] [Abstract][Full Text] [Related]
40. COPD exacerbation frequency and its association with health care resource utilization and costs. Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]